Qi Chen
Qi Chen has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Bintao Xie
State Key Laboratory of Eye Health, Eye Hospital
2 shared publicationsJineng Lv
State Key Laboratory of Eye Health, Eye Hospital
2 shared publicationsLiujun Ding
State Key Laboratory of Eye Health, Eye Hospital
2 shared publicationsQin Zhang
State Key Laboratory of Eye Health, Eye Hospital
2 shared publications- Bintao Xie
State Key Laboratory of Ophthalmology, Optometry and Vision Science, Eye Hospital Wenzhou Medical University Wenzhou Zhejiang China
1 shared publication - Cong Wang
School of Pharmaceutical Sciences, Wenzhou Medical University, University Town, Wenzhou, Zhejiang, 325035, China; Cixi Biomedical Research Institute, Wenzhou Medical University, Ningbo, Zhejiang, 315302, China
1 shared publication
Latest Publications
- 27 April 2026
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 9 (5) , 1099-1108
Bemarituzumab Suppresses Choroidal Neovascularization in Mice by Downregulating Melanoma Cell Adhesion Molecule and Yes-Associated Protein 1
In recent years, some fibroblast growth factors (FGFs) have been reported to be promising therapeutic targets for neovascular age-related macular degeneration (nAMD). Interestingly, we found that the FGFR2b inhibitor bemarituzumab (FPA144) exerts a beneficial effect in a mouse choroidal neovascularization (CNV) model. Our current study aims to uncover the potential molecular mechanism by which FPA144 alleviates CNV. The effect of FPA144 was evaluated in a laser-induced CNV mouse model. Fundus fluorescein angiography (FFA), optical coherence tomography (OCT), and choroidal flat mounts were carried out for the quantitative assessment of CNV. Label-free quantitative proteomics analysis was performed to assess changes in molecular pathways. Primary cultured human umbilical vein endothelial cells (HUVECs) were used for further confirmation of the target pathway in vitro. FFA, OCT, and choroidal flat mounts demonstrate the protective effect of FPA144 in a mouse CNV model. Compared to the control group, the treated group has smaller vascular leakage areas or smaller CNV lesions. Proteomic analyses indicate that the melanoma cell adhesion molecule (MCAM, CD146)–Yes-associated protein 1 (Yap1) pathway may be involved in the effect of FPA144. Immunostaining of choroidal flat mounts and cryosections reveals decreased expression of CD146 and Yap1 in the vascular endothelial cells of the treated animals. Experiments on HUVECs further verify the inhibitory effect of FPA144 on vascular endothelial cells. Our findings demonstrate that FPA144 can efficiently inhibit the development of choroidal neovascularization in mice by downregulating CD146 and Yap1.
- 27 April 2026
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 9 (5) , 1099-1108
Bemarituzumab Suppresses Choroidal Neovascularization in Mice by Downregulating Melanoma Cell Adhesion Molecule and Yes-Associated Protein 1
In recent years, some fibroblast growth factors (FGFs) have been reported to be promising therapeutic targets for neovascular age-related macular degeneration (nAMD). Interestingly, we found that the FGFR2b inhibitor bemarituzumab (FPA144) exerts a beneficial effect in a mouse choroidal neovascularization (CNV) model. Our current study aims to uncover the potential molecular mechanism by which FPA144 alleviates CNV. The effect of FPA144 was evaluated in a laser-induced CNV mouse model. Fundus fluorescein angiography (FFA), optical coherence tomography (OCT), and choroidal flat mounts were carried out for the quantitative assessment of CNV. Label-free quantitative proteomics analysis was performed to assess changes in molecular pathways. Primary cultured human umbilical vein endothelial cells (HUVECs) were used for further confirmation of the target pathway in vitro. FFA, OCT, and choroidal flat mounts demonstrate the protective effect of FPA144 in a mouse CNV model. Compared to the control group, the treated group has smaller vascular leakage areas or smaller CNV lesions. Proteomic analyses indicate that the melanoma cell adhesion molecule (MCAM, CD146)–Yes-associated protein 1 (Yap1) pathway may be involved in the effect of FPA144. Immunostaining of choroidal flat mounts and cryosections reveals decreased expression of CD146 and Yap1 in the vascular endothelial cells of the treated animals. Experiments on HUVECs further verify the inhibitory effect of FPA144 on vascular endothelial cells. Our findings demonstrate that FPA144 can efficiently inhibit the development of choroidal neovascularization in mice by downregulating CD146 and Yap1.
- 19 July 2025
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 24 (10) , 5001-5010
Proteomic Signatures of Choroidal Neovascularization via Integrated LC-FAIMS-MS/MS Workflow
The multicellular retinal pigment epithelium/choroid (RC) tissue is pivotal in maintaining retinal homeostasis and is closely associated with sight-threatening eye diseases. However, the limited sample amount, particularly in mice, poses a great challenge in comprehensively characterizing the functional proteins of the RC in disease models. This study utilized a state-of-the-art FAIMS device coupled with an Orbitrap Fusion Lumos mass spectrometer to systematically optimize the LC, FAIMS, and MS/MS acquisition parameters for in-depth proteomic analysis of the difficultly obtained RC samples. In a mouse model of neovascular age-related macular degeneration (nvAMD), the optimized workflow effectively increased the coverage of the proteome, which enabled the identification of 7047 proteins, compared to 5500 identified by conventional LC-MS/MS. Combined with multiomics data sets across species, differential expression analysis revealed 295 significantly altered proteins in the nvAMD model, including key regulators of extracellular matrix (ECM) remodeling (HTRA1, CCDC80) and immune response (SYK, CTSS). Functional enrichment and protein-protein interaction (PPI) network analysis highlighted critical pathways involved in neutrophil chemotaxis, ECM organization, and PI3K-Akt signaling, uncovering potential crosstalk between immune dysregulation and ECM degradation in choroidal neovascularization (CNV) progression. In conclusion, the optimized LC-FAIMS-MS/MS technique presented in this study offers an enhanced depth of proteomic analysis for the RC tissue, revealing novel insights into the molecular mechanisms of nvAMD and identifying new potential therapeutic targets.
- 19 July 2025
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 24 (10) , 5001-5010
Proteomic Signatures of Choroidal Neovascularization via Integrated LC-FAIMS-MS/MS Workflow
The multicellular retinal pigment epithelium/choroid (RC) tissue is pivotal in maintaining retinal homeostasis and is closely associated with sight-threatening eye diseases. However, the limited sample amount, particularly in mice, poses a great challenge in comprehensively characterizing the functional proteins of the RC in disease models. This study utilized a state-of-the-art FAIMS device coupled with an Orbitrap Fusion Lumos mass spectrometer to systematically optimize the LC, FAIMS, and MS/MS acquisition parameters for in-depth proteomic analysis of the difficultly obtained RC samples. In a mouse model of neovascular age-related macular degeneration (nvAMD), the optimized workflow effectively increased the coverage of the proteome, which enabled the identification of 7047 proteins, compared to 5500 identified by conventional LC-MS/MS. Combined with multiomics data sets across species, differential expression analysis revealed 295 significantly altered proteins in the nvAMD model, including key regulators of extracellular matrix (ECM) remodeling (HTRA1, CCDC80) and immune response (SYK, CTSS). Functional enrichment and protein-protein interaction (PPI) network analysis highlighted critical pathways involved in neutrophil chemotaxis, ECM organization, and PI3K-Akt signaling, uncovering potential crosstalk between immune dysregulation and ECM degradation in choroidal neovascularization (CNV) progression. In conclusion, the optimized LC-FAIMS-MS/MS technique presented in this study offers an enhanced depth of proteomic analysis for the RC tissue, revealing novel insights into the molecular mechanisms of nvAMD and identifying new potential therapeutic targets.
- 25 April 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (8) , e70570
Directed Evolution of OgeuIscB With Enhanced Activity in Human Cells
The miniature RNA‐guided endonuclease IscB, as the evolutionary progenitor of Cas9, is attracting increased attention for genome editing due to its compact size and suitability for in vivo delivery. However, the poor editing efficiency of IscB in eukaryotic cells presents a significant challenge to its widespread application in precise site‐specific human genome editing. In this study, we employed structure‐guided rational design and protein engineering to optimize OgeuIscB, resulting in the identification of enIscB‐F138R, which further enhanced editing activity up to 3.49‐fold in mammalian cells compared to the high‐activity OgeuIscB variant enIscB. Furthermore, we engineered an enIscB‐F138R nickase‐based adenine base editor, termed miABE‐F138R, exhibiting enhanced base editing efficiency relative to miABE. To illustrate the practical applications of miABE‐F138R, we applied it to rectify the prevalent R560C mutation in Pde6β associated with autosomal recessive retinitis pigmentosa, resulting in a significant improvement in activity compared to miABE. In conclusion, enIscB‐F138R and miABE‐F138R offer adaptable platforms for genome editing with potential significance in future biomedical applications.
- 25 April 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (8) , e70570
Directed Evolution of OgeuIscB With Enhanced Activity in Human Cells
The miniature RNA‐guided endonuclease IscB, as the evolutionary progenitor of Cas9, is attracting increased attention for genome editing due to its compact size and suitability for in vivo delivery. However, the poor editing efficiency of IscB in eukaryotic cells presents a significant challenge to its widespread application in precise site‐specific human genome editing. In this study, we employed structure‐guided rational design and protein engineering to optimize OgeuIscB, resulting in the identification of enIscB‐F138R, which further enhanced editing activity up to 3.49‐fold in mammalian cells compared to the high‐activity OgeuIscB variant enIscB. Furthermore, we engineered an enIscB‐F138R nickase‐based adenine base editor, termed miABE‐F138R, exhibiting enhanced base editing efficiency relative to miABE. To illustrate the practical applications of miABE‐F138R, we applied it to rectify the prevalent R560C mutation in Pde6β associated with autosomal recessive retinitis pigmentosa, resulting in a significant improvement in activity compared to miABE. In conclusion, enIscB‐F138R and miABE‐F138R offer adaptable platforms for genome editing with potential significance in future biomedical applications.